DrugPatentWatch Database Preview
Daiichi Sankyo Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for DAIICHI SANKYO, and what generic alternatives to DAIICHI SANKYO drugs are available?
DAIICHI SANKYO has twelve approved drugs.
There are fifteen US patents protecting DAIICHI SANKYO drugs.
There are two hundred and seventy-one patent family members on DAIICHI SANKYO drugs in forty-three countries and forty-seven supplementary protection certificates in fifteen countries.
Summary for Daiichi Sankyo
| International Patents: | 271 |
| US Patents: | 15 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 12 |
| Patent Litigation for Daiichi Sankyo: | See patent lawsuits for Daiichi Sankyo |
| PTAB Cases with Daiichi Sankyo as patent owner: | See PTAB cases with Daiichi Sankyo as patent owner |
Drugs and US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | RX | Yes | Yes | 9,169,250 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | RX | Yes | No | 7,955,619 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-004 | Sep 26, 2007 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | Start Trial | Start Trial | |||||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | RX | Yes | Yes | 7,955,619 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 4,855,290 | Start Trial |
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | 5,624,963 | Start Trial |
| Daiichi Sankyo | TRIBENZOR | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 200175-001 | Jul 23, 2010 | 5,616,599*PED | Start Trial |
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | 5,693,675*PED | Start Trial |
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | CAPSULE;ORAL | 021141-001 | May 26, 2000 | 6,433,026*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 625 mg | ➤ Subscribe | 2009-07-01 |
| ➤ Subscribe | Tablets | 5 mg/20 mg and 10 mg/40 mg | ➤ Subscribe | 2008-02-11 |
| ➤ Subscribe | Tablets | 5 mg, 20 mg and 40 mg | ➤ Subscribe | 2006-04-25 |
| ➤ Subscribe | Tablets | 40 mg/12.5 mg and 40 mg/25 mL | ➤ Subscribe | 2007-02-15 |
| ➤ Subscribe | Tablets | 15 mg, 30 mg, 60 mg and 100 mg | ➤ Subscribe | 2019-01-28 |
| ➤ Subscribe | Powder for Oral Suspension | 1.875 g/Packet and 3.75 g/Packet | ➤ Subscribe | 2010-04-09 |
| ➤ Subscribe | Tablets | 10 mg/20 mg and 5 mg/40 mg | ➤ Subscribe | 2008-03-31 |
| ➤ Subscribe | Tablets | 20 mg/12.5 mg | ➤ Subscribe | 2007-05-11 |
| ➤ Subscribe | Capsules | 30 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4128138 | Start Trial |
| South Korea | 101424843 | Start Trial |
| Canada | 2456841 | Start Trial |
| Spain | 2637020 | Start Trial |
| South Korea | 101506044 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1507558 | 12C0033 | France | Start Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705 |
| 1405852 | CR 2015 00052 | Denmark | Start Trial | PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| 0502314 | SPC/GB11/010 | United Kingdom | Start Trial | PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK |
| 1405852 | 2015/045 | Ireland | Start Trial | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 0503785 | 20/2009 | Austria | Start Trial | PRODUCT NAME: KOMBINATION VON OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, MIT AMLODIPINBESILAT; NAT. REGISTRATION NO/DATE: 1-27894, 1-27895, 1-27896 20081217; FIRST REGISTRATION: NL 100989, 100990, 100991 20080819 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
